Financial Performance - The company's operating revenue for 2023 was ¥722,138,705.43, a slight increase of 0.31% compared to ¥719,908,426.87 in 2022[24]. - The net profit attributable to shareholders for 2023 was ¥105,983,257.15, representing a growth of 5.28% from ¥100,667,359.97 in 2022[24]. - The total assets at the end of 2023 reached ¥3,221,439,738.99, marking a significant increase of 42.61% from ¥2,258,855,478.13 in 2022[24]. - The basic earnings per share for 2023 decreased by 9.66% to ¥0.2786 from ¥0.3084 in 2022[24]. - The cash flow from operating activities for 2023 was ¥163,748,533.75, down 16.45% from ¥195,996,737.04 in 2022[24]. - The company reported a total of ¥7,844,053.05 in non-recurring gains for 2023, compared to ¥3,271,050.26 in 2022[30]. - The company's total revenue for 2023 was CNY 722.14 million, representing a year-on-year growth of 0.31%[77]. - The revenue from external sales reached CNY 575.12 million, an increase of CNY 29.14 million, or 5.34% compared to the previous year[77]. - CMO/CDMO business generated sales revenue of CNY 145.54 million, marking a significant increase of 31.28% year-on-year[77]. - The net profit for the year was CNY 105.98 million, reflecting a growth of 5.28% from the previous year[77]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing industry, which is expected to grow significantly due to increasing healthcare demands in China[33]. - The market for specialty APIs and intermediates is projected to expand, with an estimated market growth of nearly ¥200 billion due to expiring patents of original drugs[34]. - The company is gradually transitioning to contract manufacturing for original drug developers, enhancing its market position[33]. - The company anticipates continued growth in the production and export scale of specialty APIs in the future[34]. - The CMO/CDMO market in China is projected to maintain a compound annual growth rate (CAGR) of over 18% from 2020 to 2025, with a market size exceeding 120 billion yuan by 2025[35]. - The company is actively expanding its market presence, particularly in international markets, to enhance revenue streams[7]. - The company is actively expanding its presence in international markets, particularly in Europe, North America, Japan, and South Korea, leveraging its experience with large international clients[38]. - The company is exploring opportunities in international markets to diversify its revenue streams and reduce dependency on domestic sales[153]. Research and Development - The company has an average R&D investment of 8.02% of sales over the past three years, indicating a strong commitment to innovation and technology development[38]. - The company actively invests in R&D across various therapeutic areas, including anticoagulants, antihyperglycemics, antihypertensives, and analgesics, expanding its product line[47]. - Research and development investment amounted to CNY 63.15 million, accounting for 8.75% of the total revenue, maintaining a high level of investment[77]. - The number of R&D personnel increased by 16.67% to 259, with the proportion of R&D staff in the total workforce rising to 19.02%[88]. - The company has obtained 4 new domestic invention patents during the reporting period, enhancing its intellectual property portfolio[61]. - The company has applied for multiple invention patents, with 8 patents already authorized, showcasing its commitment to innovation[152]. Operational Efficiency and Capacity - The company has over 600 reaction vessels with capacities ranging from 50 to 20,000 liters, totaling more than 3 million liters, showcasing its significant production capacity[36]. - The company has achieved wastewater treatment capacity of 1,500 tons/day and air treatment capacity of 30,000 cubic meters/hour at its first plant, demonstrating industry-leading environmental standards[37]. - The production process involves multiple stages, with dedicated workshops for high-demand products and multi-purpose workshops for others, optimizing production efficiency[52]. - The company completed the construction of the first phase of its new plant, which is expected to enhance production capacity further[73]. - The company has 12 synthesis workshops in the first plant and 4 in the second plant, with over 600 reaction vessels, indicating strong production capacity[67]. Governance and Compliance - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and management team, ensuring effective coordination and checks and balances[137]. - The board of directors consists of 9 members, including 3 independent directors, complying with relevant laws and regulations[140]. - The company emphasizes information disclosure and investor relations management, ensuring accurate and timely communication with investors[142]. - The company has implemented a performance evaluation and incentive mechanism for senior management, ensuring transparency and compliance with legal standards[143]. - The company has a complete set of governance rules and regulations, including articles of association and meeting rules, to enhance governance levels[137]. - The company has established a complete and independent financial institution, with a dedicated accounting team and an independent accounting system[146]. Risk Management - The company faces risks related to national policies and industry competition due to ongoing healthcare reforms and new pharmaceutical regulations[4]. - The company has not experienced major safety incidents but acknowledges potential risks associated with hazardous materials used in production[5]. - The company is subject to risks related to the renewal of essential operating licenses, which could impact its ability to produce and sell products[4]. - The company has implemented environmental management practices to comply with national standards, but increasing costs for waste treatment are anticipated due to stricter regulations[6]. Employee and Stakeholder Engagement - The company has a total of 1,362 employees at the end of the reporting period, with 694 in production, 27 in sales, and 510 in technical roles[170]. - The company has implemented a comprehensive training program aimed at enhancing employee skills and maintaining core competitiveness, including regular training and specialized technical training[173]. - The company emphasizes a performance-based culture, linking salary and bonuses to individual and company performance metrics[172]. - The company has established specific channels for investor communication, including dedicated phone lines and email addresses, to facilitate investor inquiries[142]. Future Outlook - The company plans to submit multiple product registration applications in various countries, including the US, Europe, and South Korea, in 2024[122]. - Future guidance indicates a focus on improving operational efficiency and increasing profit margins in the upcoming fiscal year[150]. - The company aims to improve operational efficiency, with a target to reduce costs by 5% in the upcoming fiscal year[131]. - The company plans to launch three new products in the next quarter, focusing on chronic disease management[131]. - The company is exploring potential acquisitions to strengthen its market position and diversify its product offerings[131].

证券代码：300636 证券简称：同和药业 公告编号：2024-018 江西同和药业股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于2024年4月 23日召开第三届董事会第二十一次会议和第三届监事会第十九次会 议，审议通过了《公司2023年度利润分配预案》，本议案尚需提交公 司2023年年度股东大会审议。本次利润分配预案已经公司2024年第二 次独立董事专门会议审议，并经公司全体独立董事一致同意。现将相 关事项公告如下： 一、2023年度利润分配预案情况 三年（2022年-2024年）股东回报规划》和中国证券监督管理委员会 （以下简称"中国证监会"）关于上市公司现金分红的相关规定，公 司2023年度利润分配预案为：以本次权益分派实施公告中确定的股权 登记日当日的总股本为基数，每10股派0.4元现金红利（含税），不 进行资本公积金转增股本。本次股利分配后剩余利润结转至以后年度 分配。在利润分配预案披露日至实施权益分派股权登记日期间，公司 股本若因股权激励授予行权、 ...

江西同和药业股份有限公司 2023 年度募集资金存放与使用情况 一、董事会的责任 同和药业董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》以及《深 圳证券交易所创业板上市公司自律监管指南第2号——公告格式 （2023年修订）》的相关规定编制募集资金专项报告。这种责任包括 设计、执行和维护与募集资金专项报告编制相关的内部控制，确保募 集资金专项报告真实、准确、完整，不存在虚假记载、误导性陈述或 重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 三、工作概述 我们按照《中国注册会计师其他鉴证业务准则第3101号——历史 财务信息审计或审阅以外的鉴证业务》的规定执行了鉴证业务。该准 则要求我们遵守职业道德规范，计划和实施鉴证工作，以对募集资金 专项报告是否在所有重大方面按照中国证券监督管理委员会《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 专项报告的鉴证报告 ...

2、人员信息 截至 2023 年末，立信拥有合伙人 278 名、注册会计师 2,533 名、 从业人员总数 10,730 名，签署过证券服务业务审计报告的注册会计 师 693 名。 江西同和药业股份有限公司董事会审计委员会 对公司 2023 年度年审会计师事务所履行监督职责情况报告 根据《中华人民共和国公司法》《国有企业、上市公司选聘会计 师事务所管理办法》《深圳证券交易所创业板股票上市规则》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》《江西同和药业股份有限公司章程》（以下简称" 《公司章程》"） 及《江西同和药业股份有限公司董事会专门委员会工作细则》（以下 简称" 《董事会专门委员会工作细则》"）等有关规定和要求，董事 会审计委员会本着勤勉尽责的原则，对公司 2023 年度年审会计师事 务所履行监督职责的情况汇报如下： 一、2023 年度年审会计师事务所基本情况 （一）截至 2023 年 12 月 31 日，立信会计师事务所特殊普通合 伙）基本情况如下： 1、基本信息 立信会计师事务所 （特殊普通合伙）（以下简称 "立信"）由我国 会计泰斗潘序伦博士于 1927 年在上海创 ...

Financial Performance - The company's revenue for Q1 2024 was ¥206,454,983.02, a decrease of 6.47% compared to ¥220,746,478.69 in the same period last year[5] - Net profit attributable to shareholders increased by 31.62% to ¥43,562,751.14 from ¥33,096,474.74 year-on-year[5] - Basic earnings per share rose by 9.74% to ¥0.1037, compared to ¥0.0945 in the same period last year[5] - The operating profit for the first quarter was CNY 49,031,953.90, up from CNY 35,018,129.78, indicating a growth of 40.0% year-over-year[24] - The total revenue from operating activities was CNY 156,938,328.08, a decrease of 18.6% from CNY 192,740,643.47 in the previous year[25] Cash Flow - The net cash flow from operating activities decreased significantly by 65.12% to ¥29,743,589.13, down from ¥85,264,632.48 in the previous year[11] - The cash flow from operating activities showed a net inflow of CNY 29,743,589.13, down 65.1% from CNY 85,264,632.48 in the same quarter last year[27] - The net cash flow from financing activities increased by 89.75% to ¥150,196,833.20, driven by increased borrowings[11] - The total cash inflow from financing activities was CNY 304,950,000.00, up from CNY 180,279,576.00, showing a strong increase in financing efforts[27] Assets and Liabilities - Total assets increased by 5.26% to ¥3,390,868,839.82 from ¥3,221,439,738.99 at the end of the previous year[5] - The company's total liabilities increased to ¥1,119,421,778.18 from ¥994,990,614.72, reflecting a rise of about 12.5%[22] - Non-current assets totaled ¥2,106,094,358.02, up from ¥2,024,456,028.48, marking an increase of approximately 4.0%[21] - The company's equity attributable to shareholders rose to ¥2,271,447,061.64 from ¥2,226,449,124.27, an increase of approximately 2.0%[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 14,649[12] - The largest shareholder, Mr. Pang Zhengwei, holds 15.60% of the shares, amounting to 66,009,954 shares, with 13,860,000 shares pledged[12] - The second-largest shareholder, Fenglong Industrial Co., Ltd., holds 13.12% of the shares, totaling 55,511,352 shares[12] - The top ten shareholders collectively hold significant stakes, with the largest three shareholders accounting for 30.42% of the total shares[12] Research and Development - Research and development expenses decreased by 46.42% to ¥10,292,403.05 from ¥19,210,151.13 year-on-year[10] - Research and development expenses amounted to CNY 10,292,403.05, a decrease of 46.5% compared to CNY 19,210,151.13 in the previous year[24] Operational Developments - The company completed the construction of the main structure for the new plant project, with some buildings undergoing external decoration as of 2022[18] - The company has completed the expansion and renovation of certain workshops and facilities in the new plant area, enhancing production capacity[18] Other Income and Expenses - Other income surged by 904.91% to ¥3,685,602.25, primarily due to increased government subsidies[10] - The company experienced a 190.08% increase in income tax expenses, amounting to ¥5,402,452.76, due to higher taxable income[10] - The company incurred financial expenses of CNY -5,567,941.04, contrasting with CNY 3,000,752.72 in the previous year, indicating a shift in financial management[24] Future Outlook - The report does not provide specific future performance guidance or outlook for the upcoming quarters[12] - The company has not disclosed any new strategies related to market expansion or mergers and acquisitions in this report[12] - There are no new product launches or technological developments mentioned in the current quarter's report[12] - The report indicates that there are no changes in the number of restricted shares for major shareholders during the reporting period[15] - The company has not reported any changes in the participation of major shareholders in margin financing or securities lending activities[13]

2023 年度财务决算报告 江西同和药业股份有限公司(以下简称"公司")2023 年度财务报 表按照企业会计准则的规定编制，在所有重大方面公允反映了公司 2023 年的财务状况以及 2023 年度的经营成果和现金流量。公司财务 报表已经立信会计师事务所（特殊普通合伙）审计，并出具标准无保 留意见的审计报告。现将 2023 年度合并财务报表反映的主要财务数 据报告如下： 一、 2023 年度公司财务报表的审计情况 公司 2023 年度财务报表已经立信会计师事务所审计，并以信 会师报字[2024]第 ZA11090 号文出具了标准无保留意见的审计报告。 二、主要会计数据及财务指标变动情况 | 单位：万元 | | --- | | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | 营业总收入 | 72,213.87 | 71,990.84 | 0.31% | | 营业利润 | 11,223.23 | 10,633.24 | 5.55% | | 利润总额 | 11,250.03 | 10,614.97 | 5.98% | | 净利润 | 10,598.33 ...

一、 募集资金的基本情况 招商证券股份有限公司 关于江西同和药业股份有限公司 使用闲置募集资金进行现金管理的核查意见 招商证券股份有限公司（以下简称"招商证券"）作为江西同和药业股份有限 公司（以下简称"同和药业"、"公司"）向特定对象发行股票的保荐机构，根据《证 券发行上市保荐业务管理办法》《上市公司监管指引第 2 号—上市公司募集资金 管理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易 所上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《深圳证券交易 所上市公司自律监管指引第 13 号—保荐业务》等有关规定，对公司使用闲置募 集资金进行现金管理的事项进行了核查，具体情况如下： 经中国证券监督管理委员会《关于同意江西同和药业股份有限公司向特定对 象发行股票注册的批复》（证监许可〔2023〕676 号文）文件核准，公司向特定 对象发行人民币普通股 72,926,162 股，每股面值 1 元，发行价格 10.97 元/股，募 集资金总额为 799,999,997.14 元。上述募集资金在扣除此前未支付的承销及保荐 费用含税金额 9,433,999.97 元后的实际募集资金金额为 ...

证券代码：300636 证券简称：同和药业 公告编号：2024-033 江西同和药业股份有限公司 关于选举产生第四届监事会职工代表监事的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司 规范运作》等法律法规、规范性文件及《公司章程》的有关规定，公 司拟进行新一届监事会的换届选举工作。 江西同和药业股份有限公司（以下简称"公司"）第三届监事会 任期已于2024年4月21日届满，为保证监事会的正常运作，根据《中 华人民共和国公司法》、《深圳证券交易所创业板股票上市规则》、 2024年4月23日，公司召开了职工代表大会2024年第一次会议， 与会职工代表经认真讨论、民主投票，同意选举何清元先生为公司第 四届监事会职工代表监事（个人简历见附件）。何清元先生将与公司 2023年年度股东大会选举产生的两名非职工代表监事共同组成公司 第四届监事会，任期至第四届监事会届满之日。 何清元先生，1963 年出生，中国国籍，无境外永久居留权。曾 在江西省联合纸厂担任电工、机修车间主任等职务。2003 年入职公 司，历 ...

江西同和药业股份有限公司（ 以下简称"公司"）聘请立信会计 师事务所（ 特殊普通合伙） 以下简称"立信"）作为公司 2023 年度 年报审计机构。根据（ 国有企业、上市公司选聘会计师事务所管理办 法》，公司对立信 2023 年度审计履职情况进行评估，具体情况如下： 一、会计师事务所基本情况 一）资质条件 会计师事务所名称：立信会计师事务所 特殊普通合伙） 注册地址：上海市黄浦区南京东路 61 号四楼 首席合伙人：朱建弟 江西同和药业股份有限公司 2023 年度会计师事务所履职情况评估报告 三、总体评价 2023 年度末注册会计师人数：2,533 人 2023 年度末签署过证券服务业务审计报告的注册会计师人数： 693 人 2022 年度收入总额 经审计）：461,400 万元 2022 年度审计业务收入 经审计）：340,800 万元 2022 年度证券业务收入 经审计）：151,600 万元 2022 年度上市公司审计客户家数：671 家 二）聘任会计师事务所履行的程序 公司于 2023 年 4 月 20 日、2023 年 5 月 15 日分别召开第三届董 事会第十五次会议和 2022 年年度股东大会，审议 ...

江西同和药业股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为切实维护江西同和药业股份有限公司(以下简称公司) 股东利益，规范会计师事务所选聘行为，提高财务审计质量，依据《 中 华人民共和国公司法》 中华人民共和国证券法》 国有企业、上市公 司选聘会计师事务所管理办法》 深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等有关法律、法规、规范 性文件及公司规章制度的规定，结合公司实际情况，制定本制度。 第二条 本制度所称选聘会计师事务所，是指根据相关法律法规 要求，聘任(含选聘、续聘、改聘)会计师事务所对财务会计报告发表 审计意见、出具审计报告的行为。 第三条 公司选聘会计师事务所应经董事会审计委员会(以下简 称"审计委员会") 审核后，报经董事会和股东大会审议。公司控股 股东、实际控制人不得在公司董事会、股东大会审议前，向公司指定 会计师事务所，也不得干预审计委员会独立履行选聘职责。 第二章 会计师事务所资格要求 第四条 公司聘任的会计师事务所应当具备下列条件： (一)具备国家行业主管部门和中国证券监督管理委员会(以下简 称"中国证监会")规定的开展证券期货相关业务所需的执 ...